Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Implications of occult metastatic cells for systemic cancer treatment in patients with breast or gastrointestinal cancer
Autore:
Braun, S; Rosenberg, R; Thorban, S; Harbeck, N;
Indirizzi:
Tech Univ Munich, Klinikum Rechts Isar, Klin Forschergrp, Frauenklin & Poliklin, D-81675 Munich, Germany Tech Univ Munich Munich Germany D-81675 oliklin, D-81675 Munich, Germany
Titolo Testata:
SEMINARS IN SURGICAL ONCOLOGY
fascicolo: 4, volume: 20, anno: 2001,
pagine: 334 - 346
SICI:
8756-0437(200106)20:4<334:IOOMCF>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
POLYMERASE-CHAIN-REACTION; BONE-MARROW MICROMETASTASES; GROWTH-FACTOR RECEPTOR; EPITHELIAL MEMBRANE ANTIGEN; DISSEMINATED TUMOR-CELLS; LYMPH-NODE METASTASES; MONOCLONAL-ANTIBODY THERAPY; CYTOKERATIN-POSITIVE CELLS; EARLY GASTRIC-CANCER; MEDIAN FOLLOW-UP;
Keywords:
breast cancer; colorectal cancer; gastric cancer; pancreatic cancer; oesophageal cancer; bone marrow; peripheral blood; lymph nodes; cytokeratin; prognosis; survival; adjuvant therapy; antibody therapy;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
123
Recensione:
Indirizzi per estratti:
Indirizzo: Braun, S Tech Univ Munich, Klinikum Rechts Isar, Klin Forschergrp, Frauenklin & Poliklin, Ismaninger Str 22, D-81675 Munich, Germany Tech Univ MunichIsmaninger Str 22 Munich Germany D-81675 ermany
Citazione:
S. Braun et al., "Implications of occult metastatic cells for systemic cancer treatment in patients with breast or gastrointestinal cancer", SEM SURG ON, 20(4), 2001, pp. 334-346

Abstract

The early and clinically occult spread of viable tumour cells to the organism is becoming acknowledged as a hallmark in cancer progression, since abundant clinical and experimental data suggest that these cells are precursors of subsequent distant relapse. Using monoclonal antibodies against epithelial cytokeratins or turnour-associated cell membrane glycoproteins, C individual carcinoma cells can be detected in cytological bone marrow preparations at frequencies of 10(-5 to) 10(-6). Prospective clinical studies have shown that the presence of such immunostained cells in bone marrow is prognostically relevant with regard to relapse-free and overall survival, even inmalignancies that do not preferentially metastasise to bone. As current treatment strategies have resulted in a substantial improvement of cancer mortality rates, it is noteworthy to consider the intriguing options of immunocytochemical screening of zn zn bone marrow aspirates for occult metastaticcells. Besides improved tumour staging, such screening offers opportunities for guiding patient stratification for aduvant therapy trials, monitoringresponse to adjuvant therapies (which, at present, can only be assessed retrospectively after an extended period of clinical follow-up), and specifically targeting tumour-bio C logical therapies against disseminated tumour cells. The present review summarises the current data on the clinical significance of occult metastatic cancer cells in bone marrow. (C) 2001 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/02/20 alle ore 11:50:19